Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.

Mok T, Nishio M, Yoshida T, Ahn MJ, Kudou K, Asato T, Yang H, Tong X, Vincent S, Zhang P, Yamamoto N, Kim ES

DOI: 10.1016/j.lungcan.2025.108793
Published: 2025 Nov
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108793,
  title = {Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.},
  author = {Mok T and Nishio M and Yoshida T and Ahn MJ and Kudou K and Asato T and Yang H and Tong X and Vincent S and Zhang P and Yamamoto N and Kim ES},
  year = {2025},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2025.108793},
  url = {https://doi.org/10.1016/j.lungcan.2025.108793}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.
AU  - Mok T
AU  - Nishio M
AU  - Yoshida T
AU  - Ahn MJ
AU  - Kudou K
AU  - Asato T
AU  - Yang H
AU  - Tong X
AU  - Vincent S
AU  - Zhang P
AU  - Yamamoto N
AU  - Kim ES
PY  - 2025
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2025.108793
UR  - https://doi.org/10.1016/j.lungcan.2025.108793
ER  -

APA

T, M., M, N., T, Y., MJ, A., K, K., T, A., H, Y., X, T., S, V., P, Z., N, Y., & ES, K. (2025). Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2025.108793

Source records

pubmed · retrieved 2026-09-26T03:03:00.228Z